probucol has been researched along with Hepatitis in 3 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Hepatitis: INFLAMMATION of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of probucol, an agent with strong antioxidant properties, in reversing biochemical changes in nonalcoholic steatohepatitis (NASH)." | 9.10 | Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. ( Ansari, R; Farahvash, MJ; Hormazdi, M; Khatibian, M; Malekzadeh, R; Merat, S; Mikaeli, J; Naserimoghadam, S; Sohrabi, MR; Sotoudehmanesh, R, 2003) |
| "Probucol is a lipid-lowering agent with strong antioxidant properties." | 6.71 | Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. ( Malekzadeh, R; Merat, S; Naserimoghadam, S; Rakhshani, N; Sohrabi, MR; Sohrabpour, AA; Sotoudeh, M, 2003) |
| "To evaluate the effects of probucol, an agent with strong antioxidant properties, in reversing biochemical changes in nonalcoholic steatohepatitis (NASH)." | 5.10 | Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. ( Ansari, R; Farahvash, MJ; Hormazdi, M; Khatibian, M; Malekzadeh, R; Merat, S; Mikaeli, J; Naserimoghadam, S; Sohrabi, MR; Sotoudehmanesh, R, 2003) |
| "Probucol is a lipid-lowering agent with strong antioxidant properties." | 2.71 | Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. ( Malekzadeh, R; Merat, S; Naserimoghadam, S; Rakhshani, N; Sohrabi, MR; Sohrabpour, AA; Sotoudeh, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonkovsky, HL | 1 |
| Merat, S | 2 |
| Malekzadeh, R | 2 |
| Sohrabi, MR | 2 |
| Hormazdi, M | 1 |
| Naserimoghadam, S | 2 |
| Mikaeli, J | 1 |
| Farahvash, MJ | 1 |
| Ansari, R | 1 |
| Sotoudehmanesh, R | 1 |
| Khatibian, M | 1 |
| Sotoudeh, M | 1 |
| Rakhshani, N | 1 |
| Sohrabpour, AA | 1 |
2 trials available for probucol and Hepatitis
| Article | Year |
|---|---|
Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study.
Topics: Adult; Antioxidants; Fatty Liver; Female; Hepatitis; Humans; Liver Function Tests; Male; Middle Aged | 2003 |
Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Double-Blind Met | 2003 |
1 other study available for probucol and Hepatitis
| Article | Year |
|---|---|
Optimal management of nonalcoholic fatty liver/steatohepatitis.
Topics: Alanine Transaminase; Antioxidants; Fatty Liver; Hepatitis; Humans; Oxidative Stress; Probucol | 2003 |